These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21180297)

  • 1. Beta blockers and CVD protection: new frontiers.
    Pancholia AK; Jain V
    Indian Heart J; 2010; 62(2):99-100. PubMed ID: 21180297
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta blockers and CVD protection; new frontriers.
    Chopra HK
    Indian Heart J; 2010; 62(2):98. PubMed ID: 21180296
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HOPE study: comparison with other trials of secondary prevention.
    Otterstad JE; Sleight P
    Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
    [No Abstract]   [Full Text] [Related]  

  • 11. Underuse of evidence-based therapies.
    Hlatky MA
    Circulation; 2004 Aug; 110(6):644-5. PubMed ID: 15302805
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risk reduction of acute heart failure with initial administration of beta-blockers].
    Med Monatsschr Pharm; 2007 Apr; 30(4):158. PubMed ID: 17484449
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resp-informations].
    Bouvier-Colle MH; Cot M; Le Goaster C
    Rev Epidemiol Sante Publique; 2000 Apr; 48(2):215-24. PubMed ID: 10804430
    [No Abstract]   [Full Text] [Related]  

  • 17. [Administration of beta blockers for chronic heart failure].
    Walma EP
    Ned Tijdschr Geneeskd; 2000 Nov; 144(48):2325-6. PubMed ID: 11143301
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?
    Fang JC
    Circulation; 2005 Oct; 112(16):2380-2. PubMed ID: 16230494
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of the diabetic patient with prior cardiovascular events.
    Fonarow GC
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S38-49. PubMed ID: 14668702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.